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The search for putative precursor cells within the
pancreas has been the focus of extensive research.
Previously, we identified rare pancreas-derived mul-
tipotent precursor (PMP) cells in the mouse with the
intriguing capacity to generate progeny in the
pancreatic and neural lineages. Here, we establish
the embryonic pancreas as the developmental
source of PMPs through lineage-labeling experi-
ments. We also show that PMPs express insulin
and can contribute to multiple pancreatic and neural
cell types in vivo. In addition, we have isolated PMPs
from adult human islet tissue that are also capable of
extensive proliferation, self-renewal, and generation
of multiple differentiated pancreatic and neural cell
types. Finally, both mouse and human PMP-derived
cells ameliorated diabetes in transplanted mice.
These findings demonstrate that the adult mamma-
lian pancreas contains a population of insulin+ multi-
potent stem cells and suggest that these cells may
provide a promising line of investigation toward
potential therapeutic benefit.INTRODUCTION
The search for putative precursor cells within the pancreas has
been the focus of extensive research, largely because of their
envisioned use in the generation of new b cells for therapeutic
cell replacement strategies in the treatment of diabetes.
Previous work identified a novel precursor population, termed
pancreas-derived multipotent precursors (PMPs), resident
within the adult murine pancreas (Seaberg et al., 2004). A single
PMP cell was capable of in vitro proliferation to form a clonally
derived sphere colony, which expressed both neural and
pancreatic precursor genes. Upon differentiation, clonal PMP
spheres generated a cellular output containing multiple differen-
tiated cell types of both lineages. Further, the b cells produced
de novo were found to display functional glucose-stimulated
Ca2+ responses and insulin secretion.The intriguing capacity of these cells to generate progeny of
distinct germ layers—endodermal pancreatic and ectodermal
neural—raises questions as to their in vivo identity and ontogenic
developmental compartment. Use of an in vitro sphere formation
assay, while facilitating study of these cells, does not yield any
prospective information regarding the in vivo characteristics of
the PMP cells. We found that the mouse PMP cells do not
express nestin as a specific marker, nor do they have an ESC
or mesodermal precursor character (Seaberg et al., 2004). The
neural crest (NC) was considered as the ontogenic origin of
PMP cells, because it is a developmental structure that has
a broad contribution to various lineages and has been proposed
to be the source of most, if not all, highly plastic adult stem cells
(Pierret et al., 2006). Though PMP sphere colonies were found
not to express genes associated with the NC, such as P75,
Pax3, Twist, Sox10, and Wnt1 (Seaberg et al., 2004), their
absence does not rule out a NC origin. The current study
resolves this issue by including NC lineage-labeling and PDX-1
lineage-labeling experiments, which exclude the NC, and estab-
lishes the embryonic PDX-1 lineage as the source of PMP cells in
the adult.
Although it has been known that b cells retain a limited
capacity for replication (Messier and Leblond, 1960; Kassem
et al., 2000), a surprising study by Dor et al. (2004) argued that
new b cells in the adult were formed exclusively by self-duplica-
tion without any contribution from stem cell differentiation. This
study generated controversy within the field, because it
challenged the significance of work from many groups investi-
gating the existence and role of putative adult pancreatic stem
cells. Another recent study from the same group furthered these
findings to suggest that there are no pancreatic stem cells in the
developing embryo nor the adult and that the pancreas is formed
by progenitors that are autonomously restricted, capable of
producing only a fixed amount of tissue (Stanger et al., 2007).
In the Dor et al. (2004) study, the authors utilized an elegant
lineage-tracing technique by using mice with a tamoxifen-induc-
ible transgene driving expression of the Cre recombinase
enzyme under control of the rat insulin promoter (RIP-Cre-ER
mice). After breeding with a reporter mouse strain, tamoxifen
injections induced indelible labeling of insulin-expressing cells
and their progeny. Dor et al. (2004) provided evidence that new
b cells were generated entirely from such lineage-labeled cells,
and thus concluded that old b cells were the source of new.
However, such a conclusion is based on the assumption thatCell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc. 281
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lary point that any putative stem cells would not express insulin.
This may not necessarily be true, because stem cells may
express ostensible differentiation markers in vivo, as has been
observed with the expression of GFAP, a differentiated astrocyte
marker, in neural stem cell populations within the brain
(Morshead et al., 2003). As such, it is possible that any putative
pancreatic stem cell population actually may express insulin
in vivo. To investigate whether our PMP cell population ex-
pressed insulin in vivo, we used transgenic mice constitutively
expressing GFP under control of the mouse insulin promoter
(MIP-GFP mice) (Hara et al., 2003). In addition, the same
RIP-Cre-ER mice used by Dor et al. (2004) were employed to
verify the findings obtained with the MIP-GFP mice and to
explore the lineage potential of insulin+ cells in vivo. These exper-
iments demonstrate conclusively that the PMP cells do indeed
express insulin in vivo and that insulin+ cells have the capacity
to generate multiple types of pancreatic and neural cells in vivo
in the normal adult pancreas.
We also sought to determine whether the human pancreas
contained cells analogous to the PMP cells that we have identi-
fied in mice. It was found that adult human islet tissue contained
cells capable of clonal proliferation to form colonies that were
self-renewing and multipotent in the neural and pancreatic line-
ages, which produced functional b cells. The therapeutic poten-
tial of PMPswas then established by transplantation of mouse or
human PMP-derived cells into diabetic mice. Thus, PMP cells
represent an insulin-expressing multipotent stem cell population
resident within the adult mammalian pancreas.
RESULTS
Pancreas, and Not Neural Crest, Is the Embryonic
Source of PMP Cells
We have demonstrated by RT-PCR analysis that clonal spheres
produced by proliferating PMP cells do not express genes asso-
ciated with the NC (Seaberg et al., 2004); however, the transient
nature of these markers is such that their absence in adult cell-
derived colonies does not preclude a NC origin for PMP cells
during development. To address this, we employed transgenic
mice expressing the Cre enzyme under the control of the Wnt1
promoter (Wnt1-Cre mice) (Danielian et al., 1998).Wnt1 expres-
sion is restricted to theNC in the periphery (Echelard et al., 1994).
Crossing theWnt1-Cremicewith the Z/EG reporter strain (Novak
et al., 2000) yielded mice in which the NC lineage remained fluo-
rescently labeled with GFP. Confocal visualization of pancreatic
sections from these Wnt1-Cre 3 Z/EG mice revealed the pres-
ence of GFP+ cells displaying process-bearing morphologies,
not typically observed in pancreatic exocrine and endocrine
cells, which represent peripheral neuronal or Schwann cells
(not shown). Primary cells from both islet and ductal tissue
compartments were subjected to FACS followed by plating of
positive and negative fractions in the PMP sphere formation
assay. FACS showed that 5.0% ± 0.2% of primary islet and
4.1% ± 0.3% of duct compartment cells were fluorescent and
thus derived from the NC. Notably, 100% of the PMP spheres
were generated by cells in the sorted negative fraction. At day
4 of the assay, the negative cells were already proliferating to
form spheres, whereas the positive cells were largely adherent,282 Cell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc.developing spindle-like morphologies by day 8 (not shown).
These data show that all PMP spheres came from unlabeled cells
and thus verify that the sphere-initiating PMP cells are not NC
derived. To determine whether PMPs arose from a pancreatic
endoderm source developmentally, we utilized PDX-1-Cre
(Gu et al., 2002) 3 Z/EG mice to GFP label the entire PDX-1
lineage in adult mice. FACS of primary cells and plating of sorted
fractions in the PMP assay revealed that the GFP+ cell fraction
had higher sphere-formation capacity (4.0 ± 1.2 spheres/10,000
cells) than did the GFP fraction (0.9 ± 0.5 spheres/10,000 cells).
As a result, the vast majority (95.2% ± 0.6%) of spheres came
from the GFP+ cell fraction, verifying that the PMP cell arose
from a PDX-1+ pancreatic lineage developmentally.
PMP Cells Express Insulin In Vivo
Published studies have suggested that any newly generated
b cells in vivo arise from insulin-expressing cells (Dor et al.,
2004). To determine whether PMP cells express insulin in vivo,
transgenic MIP-GFP mice were used. b cells within islets fluo-
resced with GFP (Figure S1A available online). We verified the
fidelity of the transgene by immunostaining of primary cells.
The insulin+ cells were GFP+, the GFP+ cells were C-peptide+,
and both glucagon+ and somatostatin+ cells were GFP (Figures
S1B–S1E). Primary cells from both islet and ductal tissue
compartments were subjected to FACS followed by plating of
GFP-positive and -negative fractions in the PMP sphere forma-
tion assay. The positive fractions contained sphere-initiating
cells at a frequency 50-fold greater than the negative fractions
(4.59 ± 0.81 and 0.09 ± 0.04 spheres/10,000 cells, respectively).
On average, 95.3% ± 2.1% of the resultant spheres were
generated by cells within the positive fractions. Indeed, in two
of four experiments, 100% of the islet-derived spheres arose
from the positive fraction. In an effort to discriminate subpopula-
tions of insulin+ cells, the MIP-GFP-positive fraction was sorted
based on antibody staining to the b cell surface glucose trans-
porter, Glut-2 (Figure S1F), and 100% of the resultant spheres
arose from the sorted Glut-2low cell fraction. These data show
that PMP cells do in fact express insulin in vivo but do not display
a mature b cell phenotype, as evidenced by low Glut-2
expression.
The spheres produced (Figure 1A) from the single insulin-ex-
pressing GFP+ PMP cell do not then express GFP uniformly in
all cells (58.8% ± 3.8% of sphere cells were GFP+), as we might
expect if these multipotent sphere colonies were capable of
producing other pancreatic and neuronal progeny in addition
to b cells. To demonstrate the multipotentiality of the clone-initi-
ating GFP+ PMP cell, spheres from the positive fraction were
differentiated and subsequently immunostained. The generation
of insulin-expressing b cells was confirmed by staining for
insulin, which colocalized with the GFP from the transgene (Fig-
ure 1B). Coexpression of PDX-1 andGFPwas also observed (not
shown). The MIP-GFP transgene further allowed for FACS
sorting of b cells from the differentiated spheres, which were
then subjected to electron microscopy analysis. Figure 1C
shows a sample electron micrograph of an in vitro-generated
b cell, displaying archetypical b cell cytoarchitecture, including
many large dense-core insulin granules. Other endocrine cell
types were also produced. Note that the expression of glucagon
in a cells (Figure 1D) and somatostatin in d cells (Figure 1E) did
Figure 1. Insulin-Expressing Cells fromMIP-GFPMice Proliferate to
FormPMPSpheres that AreMultipotent in the Pancreatic andNeural
Lineages
(A) Spheres formed by proliferation of a single GFP+ insulin-expressing cell do
not display insulin expression in all cells.
(B–D) Such spheres could be differentiated to yield (B) insulin+/GFP+ b cells,
one of which is shown in an electron micrograph (C), as well as (D) glucagon+
a cells and (E) somatostatin+ d cells. Note that glucagon and somatostatin
expression does not overlap with that of GFP.
(F) The same clonally derived sphere that generated GFP+ insulin-expressing
b cells was also able to produce b3-tubulin+ neurons.
Cell nuclei are stained blue. Scale bars represent 50 mm in (A), (B), (E), and (F),
1 mm in (C), and 25 mm in (D). See also Figure S1.
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cross-germ layer potential, the differentiated colonies were
stained for the neuronal marker b3-tubulin, which labeled distinct
cells with obvious neuronal morphologies in the same clonally
derived sphere that produced GFP+ insulin-expressing b cells
(Figure 1F).
To verify the findings obtained with the constitutive MIP-GFP
mice, the inducible RIP-Cre-ER mice used in Dor et al. (2004)
were crossed with the Z/EG strain. Adult RIP-Cre-ER 3 Z/EG
mice were injected with 6 mg tamoxifen every 2 days (three
injections total), and the mice were sacrificed 1 day after the final
injection. This protocol GFP-labeled a percentage of the in vivo
insulin-expressing cells, with inherited labeling of the progeny
of these cells. Primary islets displayed GFP expression in a frac-
tion of total cells (Figure 2A). As a control, tamoxifen was admin-
istered to Z/EGmice, and noGFP expression was observed. Cell
quantification of immunostained pancreatic sections (fixed at
time of sacrifice) revealed that 26.3% ± 1.4% of insulin+ cells
were GFP+ (Figure 2B). Primary cells from both islet and ductal
tissue compartments were subjected to FACS followed by
plating of positive and negative fractions in the PMP sphere-
formation assay. As expected, clonal spheres were generated
from both fractions (Figures 2C and 2D), with 35.8% ± 6.6%
arising from the positive fraction (at a frequency of
3.56 ± 0.52 spheres/10,000 cells) and 64.2% ± 6.6% from the
negative fraction (at a frequency of 1.06 ± 0.20 spheres/10,000
cells). Spheres derived from the positive fraction were
composed of 98.9% ± 0.3% GFP+ cells (indicating very rare
transgene shutoff), whereas sphere cells from the negative frac-
tion were GFP. The presence of PMP cells was expected in
both fractions, because tamoxifen induction of the transgene
occurred within only a portion of the insulin-expressing cells
(Dor et al., 2004), and thus there were insulin-expressing cells
in both fractions. The multipotentiality of the clonal spheres
derived from a single GFP+ cell was confirmed by differentiation
and immunostaining (Figure S2). The formation of PMP spheres
from the positive fraction confirms that PMP cells arise from an
insulin-expressing cell population in vivo.
Insulin-Expressing Cells within Undifferentiated PMP
Spheres Are Distinct from Mature b Cells and Exhibit
a Precursor Phenotype
The present data indicate that PMP cells represent a rare insulin+
precursor population comprising a very small subset of the larger
population of insulin-expressing cells in vivo. Given this finding,
we sought to better characterize the insulin-expressing cells
within the undifferentiated PMP spheres and to compare them
to the insulin-expressing cell population within adult pancreatic
islets (predominantly mature b cells). To do this, we applied
FACS to primary pancreatic islet cells and PMP sphere cells
from MIP-GFP mice (Figure S3), allowing us to obtain two pure
populations of insulin-expressing cells from these distinct sour-
ces. Subsequently, RT-qPCR analysis was performed to assess
the expression levels of key pancreatic genes (Figure 3A). Inter-
estingly, the expression levels of both murine insulin genes were
substantially lower in the PMP-derived cells as compared to the
islet-derived cells. The low insulin mRNA expression revealed by
qPCR could be validated at the protein level by the MIP-GFP
transgene product’s fluorescence intensity (measured duringCell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc. 283
Figure 2. PMP SpheresWere Generated by Cells in the GFP-Positive
and GFP-Negative Cell Fractions from RIP-Cre-ER 3 Z/EG Mice
Tamoxifen injections into RIP-Cre-ER 3 Z/EG mice labeled a fraction of
insulin-expressing cells with GFP in (A) live primary islets and (B) in immuno-
stained pancreatic sections. Cell nuclei are stained blue. After FACS and
plating in the PMP sphere assay, single cells from both the (C) GFP+ and (D)
GFP cell fractions were capable of producing PMP spheres. Scale bars
represent 100 mm. See also Figure S2.
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Insulin+ Stem Cells in the PancreasFACS), as shown by the fact that the median GFP intensity of the
PMP-derived cells was 31.2% ± 13.2% of that observed for the
islet-derived cells. On the contrary, PDX-1 and Nkx6.1 expres-
sion were observed in the PMP-derived cells at levels compa-
rable to those of the islet-derived cells (Figure 3A). Moreover, it
appeared that Ngn-3 expression in the PMP-derived cells284 Cell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc.was actually higher than the levels observed in islet-derived
cells, consistent with our detection of rare insulin+/Ngn-3+ cells
in the normal adult pancreas (Figure S4). Notably,Glut-2was ex-
pressed at near-absent levels in the PMP-derived cells, whereas
levels in the islet-derived cell population were much higher. The
low level of Glut-2 within insulin-expressing cells of undifferenti-
ated PMP spheres is similar to the in vivo PMP cell phenotype
(see preceding section) and was confirmed by immunostaining
and confocal analysis of BalbC pancreatic islet and PMP sphere
sections (Figure 3B). Additionally, we extracted another relevant
parameter from the FACS analysis. Mature b cells exhibit a high
level of granularity because of their content of many large dense-
core insulin granules, which translates to increased FACS side-
scatter. The FACS side-scatter profiles (Figure S3) revealed
that the PMP-derived cells displayed a median side-scatter
that was 44.7% ± 0.6% of that displayed by the islet-derived
cells. Collectively, these data indicate that the insulin-expressing
cells within a PMP sphere display characteristics distinguishing
them from mature b cells and appear to exhibit a precursor
phenotype. Additional RT-qPCR experiments demonstrated
that the precursor phenotype of PMP spheres was dissimilar
from that of mesenchymal stem cell (MSC) populations derived
from the bonemarrow (Figure S5), further supporting their unique
identity.
Insulin-Expressing Cells Generate Multiple Pancreatic
and Neural Cell Types In Vivo
The present data demonstrate that a subset of the insulin-ex-
pressing cells in vivo (i.e., PMPs) represent a population of cells
that have been characterized to possess precursor properties
in vitro; however, the question remains as to whether they
function in vivo as precursor cells and whether they are relevant
to normal adult pancreatic cell turnover. To address this, adult
RIP-Cre-ER 3 Z/EG mice injected with tamoxifen were main-
tained for 10 weeks after the final injection before sacrifice. This
was the ‘‘chase’’ group ofmice, as opposed to the ‘‘pulse’’ group
that was sacrificed 1 day after the final injection. Because these
mice are insulin lineage labeled, any evident GFP+ cells arose
from an insulin-expressing cell in vivo. Tissue sections from the
pulse and chase groups were immunostained and subjected to
confocal microscopy analysis to carefully characterize the
GFP+ cell population. The percentage of insulin+ cells labeled
with GFP did not change significantly between the pulse and
chase groups (Figure 4A). Notably, however, after the 10-week
chase period, 14.2% ± 4.6% of the GFP+ cells were insulin,
whereas virtually all (99%) GFP+ cells in the pulse group were
insulin+ (Figures 4B and 4C), indicating that insulin+ cells had
given rise tonon-bcells in vivoduring thechaseperiod.Additional
immunostaining analysis revealed the presence in vivo of various
GFP+ pancreatic cell types, with a large increase observed
comparing the chase to the pulse groups. These included endo-
crine glucagon+ a cells, somatostatin+ d cells, and exocrine
amylase+ cells (Figures 4D–4F). Further, GFP+ neural cell types
were observed, with GFP coexpressed by GFAP+ glial cells and
by Neurofilament-M+ and MAP2+ neuronal cells (Figures
4G–4I). Quantification was performed to determine the
percentage of some of the marker-positive cells relative to the
entire GFP+ cell population in both the pulse and chase groups
(Figure 4J), illustrating the progressive production of non-b cells
Figure 3. Insulin-Expressing Cells within Undifferentiated PMP Spheres Are Distinct from Mature b Cells
(A) RT-qPCR analysis of key genes expressed in FACS-purified populations of insulin-expressing cells from MIP-GFP undifferentiated PMP spheres and islets
revealed that they displayed distinct profiles. Error bars are ±SEM.
(B) Confocal slice micrographs of BalbC pancreatic islet and undifferentiated PMP sphere sections, immunostained for insulin and Glut-2. Cell nuclei are stained
blue. Scale bars represent 25 mm.
See also Figures S3–S5.
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chase period. The presence of rare GFP+ cells expressing the
above markers in the pulse group indicates that even during the
6 days from tamoxifen injection commencement, insulin+ cells
had given rise to these other cell types. Additional quantification
was performed to assess the contribution of GFP+ cells to each
marker+ population (Figure 4K), demonstrating significant partic-
ipation of insulin+ precursor cells in normal adult cell turnover
within these non-b cell populations. For this interpretation to be
accurate, we needed to verify that tamoxifen induction initiated
GFP expression exclusively in insulin-expressing cells. This
was performed by tracking GFP expression upon in vitro admin-
istrationof tamoxifen,whichconfirmedboth the insulin specificity
of GFP initiation in the short term and the multipotentiality of
insulin+/GFP+ cells over several days in vitro (Figure S6). Thus,
these data recapitulate the in vitro demonstrated PMP cell multi-
potentiality, with multiple pancreatic and neural cell types being
generated in vivo from insulin+ precursor cells.
Human PMP Cells
The current and previous results (Seaberg et al., 2004) demon-
strate the existence of PMPs and characterize some of theirproperties, but they are limited to the mouse species. To extend
our studies to largermammals, we obtained adult human pancre-
atic tissue (n = 17 individuals) and sought to determine whether it
contained PMP cells analogous to those we identified in mice.
Plating of dissociated human islet tissue in our PMP sphere assay
conditions revealed that it contained cells capable of proliferation
to form clonal spheres (Figure 5A, inset) at a frequency of
2.6 ± 0.1 spheres/10,000 cells (Figure 5A), a range similar to that
seen inmouse (Seaberg et al., 2004). Further, thesespheres could
be dissociated and subcloned to yield secondary and tertiary
sphere colonies (Figure 5A). As a verification of proliferation,
primary spheres were grown in the presence of BrdU, and subse-
quent immunostaining revealed the BrdU positivity of the sphere
cells, including cells expressing insulin (Figure S7). To determine
the character of the human spheres, we performed RT-PCR anal-
ysis. Table S1 shows that the spheres expressed a panel of neural
precursor genes (nestin,Sox2,Hash-1,Ngn-1,Ngn-3,Olig-1, and
Pax-6), early endodermal markers (HNF3b, HNF4, and Gata-4),
and the pancreatic transcription factor PDX-1. Some of these
‘‘neural’’ precursor genes are also normally expressed in the
pancreatic lineage (e.g., Ngn-3, Pax-6) (Zhang and Sarvetnick,
2003). Early mesodermal markers (brachyury, Gata-1) were notCell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc. 285
Figure 4. Insulin-Positive Cells Generate
Multiple Pancreatic and Neural Cell Types
In Vivo
(A–I) Confocal analysis of immunostained pancre-
atic sections from pulse and chase groups of
RIP-Cre-ER 3 Z/EG mice showed (A) no increase
in the percentage of insulin+ cells labeled with
GFP, (B) while the percentage of GFP+ cells ex-
pressing insulin dropped during the chase period,
as can be seen in (C), in which GFP+/insulin cells
are indicated by an arrowhead. The insulin-lineage
cells gave rise to multiple cell types coexpressing
GFP (marked by arrowheads), including pancre-
atic (D) glucagon+ a cells, (E) somatostatin+ d cells,
(F) amylase+ exocrine cells; neural (G) GFAP+ glial
cells; and (H) neurofilament-M+ and (I) MAP-2+
neuronal cells. All images are a single confocal
slice, except for MAP-2, which is a z-stack (8 mm
thick). Cell nuclei are stained blue. Scale bars
represent 10 mm.
(J and K) Quantification of these marker+/GFP+
cells for both the pulse and chase groups is shown
(J) as the percentage of GFP+ cells expressing
eachmarker, and (K) as the percentage of the total
marker+ cell population that was labeled with GFP.
Error bars are ±SEM. *p < 0.01 versus pulse in (B),
*p < 0.001 versus respective pulse in (K)–(J). See
also Figure S6.
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both a neural and pancreatic precursor character. To provide
additional characterization, RT-qPCR analysis was performed
for various key pancreatic genes, comparing the human PMP
spheres to primary human islets (Figure 5B). Whereas the
expression level of insulin was perhaps somewhat lower in the
PMP spheres, it appeared that the human PMP spheres ex-
pressed substantially higher levels of PDX-1, Nkx6.1, Ngn-3,
Pax-6, and Pax-4 and substantially lower levels of Glut-2 (similar
to the mouse data), consistent with a precursor phenotype.
The human PMP spheres were then differentiated and immu-
nostained to examine their differentiation potential. Generation
of b cells was observed by the coexpression of insulin and
C-peptide (not shown) and insulin and PDX-1 (Figure 6A), as
well as coexpression of insulin with the b cell glucose transporter
Glut-2 (Figure 6B). The b cells comprised 11.6% ± 1.1% of the286 Cell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc.differentiated cell population. In addition,
other pancreatic glucagon+ and somato-
statin+ endocrine (Figure 6C) and
amylase+ exocrine (Figure 6D) cell types
were generated. Demonstrating the
neural potential of the human spheres,
the same clonally derived spheres that
produced C-peptide+ b cells also yielded
b3-tubulin+ neurons (Figure 6E). Mature
neuron production was evidenced by the
expression of MAP-2 (Figure 6F) and glial
cell generation was demonstrated by the
presence of GFAP+ (Figure 6G) and O4+
(Figure 6H) cells. Occasionally, somato-
statin+ cells with a neuronal morphologywere observed (not shown), possibly suggesting the production
of this neuroendocrine cell subtype. RT-PCR analysis of the
differentiated spheres verified expression of the differentiated
neural and pancreatic cell markers as well as an expanded array
of mature b cell markers, whereas themuscle transcription factor
MyoD was not observed (Table S2). To determine whether the
human PMP spheres had an ESC-like character, undifferentiated
spheres were immunostained for the ESCmarkers Oct-4, nanog,
SSEA-4, and Tra-160, whose expression was found to be absent
in PMP sphere cells (not shown).
Insulin content measurements were performed on differenti-
ated human PMP spheres. They contained 24.8 ± 2.9 ng of
insulin/mg of DNA whereas primary human islets contained
204.3± 27.9 ngof insulin/mgofDNAor3.3±0.5ngof insulin/differ-
entiated PMP sphere and 45.5 ± 8.8 ng of insulin/islet. To demon-
strate the functionality of the newly generated b cells, insulin
Figure 5. Human Islet Tissue Contains Cells
Capable of Proliferation to Form Self-
Renewing PMP Sphere Colonies, which
Display a Precursor Gene Expression
Profile
(A) Primary human islets were dissociated into
single cells and cultured in the PMP sphere forma-
tion assay. Rare cells proliferated to form spheres
(inset), which could be dissociated and subcloned
to produce secondary and tertiary spheres. Scale
bar represents 25 mm.
(B) RT-qPCR analysis of key genes comparing
human PMP spheres (hPMP) to human islets
(hIslet) suggested that the PMP spheres
possessed a distinct precursor character.
Error bars are ±SEM. ANOVA F(2) = 66.7;
*p < 0.001 versus primary in posttest in (A). See
also Figure S7 and Table S1.
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over a 1 hr period under low-glucose (2.5 mM) conditions was
38.9 ± 8.4 pg insulin/differentiated PMP sphere. Insulin release
stimulated by high glucose (20 mM) was 2.4- ± 0.5-fold of low
glucose-stimulated insulin secretion (Figure 6I). The insulin
release stimulated by high glucose could be moderately
enhanced by GLP-1 (30 nM), a physiological enhancer of insulin
secretion (MacDonald et al., 2002), or by tetraethylammonium
(TEA; 10 mM), a compound that inhibits delayed rectifier K+
currents, prolonging cellular depolarization, and thus potentiating
the glucose-stimulated insulin response (Roe et al., 1996). The
voltage-dependent Ca2+ channel blocker Verapamil (100 mM)
abolished glucose-stimulated insulin release (Figure 6I). The lack
of robust enhancement of insulin release by GLP-1 inclusion
during the secretion assay may be due to the prolonged contin-
uous exposure to GLP-1 during the differentiation conditions.
One of the primary modes of GLP-1 action is via cAMP signaling
(MacDonald et al., 2002). Therefore, a combination of the
membrane-permeable cAMP analog pCPT-cAMP (100 mM) and
the cAMP phosphodiesterase inhibitor IBMX (500 mM) was used
to potently activate cAMP-induced insulin secretion (Figure 6I).
This combination showed a much-increased enhancement of
glucose-stimulated insulin release. These data demonstrate that
human islet tissue contains a population of multipotent PMP cells
with the capacity to generate functional b cells.
PMP Sphere Transplantation Improves the Diabetic
State in Mice
Although we have demonstrated the generation of nascent func-
tional b cells from PMPs in vitro, a critical first step to envisionedCell Stem Cell 8, 281–2future therapeutic applications is to test
their in vivo function in the glycemic
improvement of diabetic mice after
transplantation of PMP-derived cell
populations. As such, we undertook
experiments in which streptozotocin
(STZ)-induced diabetic BalbC and NOD-
Scid mice were used as recipients for
transplantation of mouse and human
PMP spheres, respectively. Given thatwe have not yet achieved high-efficiency b cell production
in vitro from PMPs (5% mouse and 11% human b cells in
differentiated PMP colonies; see above and Seaberg et al.
[2004]), and in light of recent reports that the in vivo environment
promotes differentiation/maturation of b cells from embryonic
stem cell-derived endodermal pancreatic precursors (Kroon
et al., 2008), we reasoned that we might be able to enhance
mature b cell yield by using undifferentiated PMP spheres for
transplantation. Diabetogenesis was initiated by single injection
of STZ, and 7 days later micewith comparable levels of hypergly-
cemia were selected for transplant and control groups. Non-
fasted blood sugar levels were then monitored twice a week
for 50 days posttransplant. Transplantation of either mouse
(Figures 7A and 7B) or human (Figures 7F and 7G) PMP spheres
produced a significant amelioration of hyperglycemia, with the
mouse PMPs having an effect comparable to that observed
with transplantation of similar numbers of mouse islets (group
averages are shown in Figures 7A and 7F and individual mouse
data are shown in Figures 7B and 7G). The effectiveness of
PMP sphere transplantation was also supported by body weight
data (in whichweight at 50 days posttransplant was compared to
weight on STZ-injection date). STZ-diabetic BalbC mice that did
not receive transplants lost 1% of their body weight, whereas
this weight loss was reversed in mouse islet and PMP sphere
recipients (3.2% and 3.5% weight gain, respectively) (Fig-
ure 7C). A similar mitigation of weight loss was observed with
human PMP sphere transplantation (Figure 7H), but it appeared
that the nontransplanted diabetic NOD-Scid mice displayed
more severe weight loss than did their BalbC counterparts
(12.3% versus 1% loss, respectively), and the effect of the93, March 4, 2011 ª2011 Elsevier Inc. 287
Figure 6. Human PMP Sphere Colonies
Generate Multiple Pancreatic and Neural
Cell Types upon Differentiation, and De
NovoGenerated bCells Demonstrate Regu-
lated Glucose-Stimulated Insulin Release
(A–D) Individual PMP spheres derived from
single human islet cells could be differ-
entiated to produce (A) insulin+/PDX-1+ cells, (B)
insulin+/Glut-2+ b cells, (C) glucagon+ a cells and
somatostatin+ d cells, and (D) amylase+ exocrine
cells.
(E) The same clonally derived sphere that
produced C-peptide+ b cells was also capable of
generating b3-tubulin+ neurons.
(F–H) MAP-2 expression demonstrated the
production of mature neurons (F), and glial cell
generation was demonstrated by the presence of
(G) GFAP+ astrocytes and (H) O4+ oligodendro-
cytes. Cell nuclei are stained blue.
Scale bars represent 25 mm.
(I) Differentiated human PMP sphere colonies ex-
hibited increased insulin secretion in response to
high glucose (HG), an effect that could be
enhanced by addition of GLP-1 or TEA. Inclusion
of verapamil (Verap) abolished the glucose-stimu-
lated insulin release, while the combination of
pCPT-cAMP (cAMP in figure) with IBMX provided
potent augmentation. Error bars are ±SEM.
ANOVA F(5) = 7.3; *p < 0.05 versus low glucose
(LG), zp < 0.05 versus HG in posttest.
See also Table S2.
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demonstrate a clear effect of PMP sphere transplantation in
improving both glycemic control and body weight preservation
in diabetic recipients.
The maintained glycemic improvement observed in PMP
sphere recipients indicated that the grafted spheres differenti-
ated to yield functional b cells which persevered throughout
the analysis period. To confirm this, we sectioned and immuno-
stained the kidneys of recipient mice to assess for the presence
and fate of grafted cells. As shown in Figures 7D and 7E, clusters
of insulin+ b and glucagon+ a cells were found in the renal
subcapsular region of mouse PMP sphere-transplanted kidneys.
As a control, the nontransplanted kidneys of recipient mice
were analyzed, and no pancreatic hormone+ cells were evident
(not shown), substantiating that the hormone+ cells observed in
the transplanted kidneys were graft derived. Perdurance of
human insulin+ b cells derived from the transplanted human
PMP spheres was evident in the recipient kidneys (Figures 7I288 Cell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc.and 7J). To unambiguously verify the
human graft origin of these cells, immu-
nostaining was performed against human
nuclear antigen, which displayed nuclear
costaining in the insulin+ cells. Although
the functional nature of these human
PMP graft-derived insulin+ cells is indi-
cated by the improved glycemia, their
in vivo functionality was more directly as-
sessed by ELISAmeasurement of plasma
human C-peptide levels (Figure 7K). Theplasma humanC-peptide levels of the human PMP sphere recip-
ients was 173 ± 30 pM, 20% of that measured in nonfasted
human plasma samples (838 ± 124 pM). These data establish
the functional perseverance of both mouse and human PMP
graft-derived b cells in diabetic recipients.
DISCUSSION
This study demonstrates that the adult mammalian pancreas
contains a small population of insulin+ multipotent stem cells,
capable of dividing and contributing to the pancreatic and neural
lineages. The particular bilineage cross-germ layer potency
exhibited by these adult PMP cells raises questions regarding
their ontogenic origin and in vivo identity. PMPs do not appear
to be generalized endodermal/ectodermal precursors, because
they do not generate nonpancreatic endodermal progeny
(e.g., hepatocytes) or nonneural ectodermal progeny (e.g.,
epidermal cells) (Seaberg et al., 2004). Rather, they appear to
Figure 7. PMP Sphere Transplantation Ameliorates the Diabetic State in Recipient Mice
(A–J) Transplantation of (A–E) mouse islets or PMP spheres or (F–K) human PMP spheres under the kidney capsule of STZ-diabetic mice was performed. This
resulted in both (A, B, F, G) a reduction of hyperglycemia (group averages are shown in A and F and individual mouse data are shown in B andG) and (C, H) weight
loss in recipient mice. Confocal postanalysis of the transplanted kidneys from recipient mice revealed the perseverance of graft-derived cells.
(D and E) Low-power (103 obj.) and high-power (603 obj.) magnifications of graft-derived immunostained insulin+ and glucagon+ cells in mouse PMP sphere
recipient kidneys.
(I and J) Low-power (103 obj.) and high-power (603 obj.) magnifications of graft-derived immunostained insulin+ and human nuclear antigen (HuNu)+ cells in
human PMP sphere recipient kidneys.
Cell nuclei are stained blue. Scale bars represent 25 mm.
(K) An ELISA assay was performed, demonstrating substantial levels of circulating human C-peptide in the plasma of human PMP sphere recipients.
Error bars are ±SEM. *p < 0.05 versus No Transplant in (C) and (H); *p < 0.001 versus No Transplant in (K).
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output. This distinct potency appears unique to PMP cells, which
have neither an ESC-like nor mesodermal character (Seaberg
et al., 2004). The NC was considered as the ontogenic origin of
PMP cells, because it is a developmental structure with broad
contribution to various cell types and lineages (Dupin et al.,
2006). The NC is thought to be the source of adult multipotent
skin-derived precursors (SKPs) (Fernandes et al., 2004) and
has been hypothesized to be the source of most adult stem
cell populations (Pierret et al., 2006). The current study used
genetic lineage-tracing techniques to exclude the NC and to
establish the PDX-1+ embryonic pancreatic endoderm as the
PMP source. One of the rather interesting characteristics of
PMPs is their ability to generate neural cells, even in vivo,
a finding which is further supported by the observation that not
all neural cells were GFP+ in the Wnt1-Cre 3 Z/EG NC lineage-
labeled mice (unpublished observations), indicating a non-NC
origin for these intrapancreatic neural cells.
Some key findings, demonstrated through the use of two
different transgenic mouse models, were that the PMP cell
expresses insulin in vivo and that insulin+ cells within PMP
spheres have a precursor character distinct from mature b cells.
Thus, PMP cells display gene expression properties generally
thought to be restricted to differentiated b cells within the
pancreas. The finding that PMP cells have low expression of
Glut-2 suggests that they may not display functional properties
of b cells (i.e., regulated insulin secretion) andmay have a unique
stem cell identity. The lack of Glut-2 was maintained in the
insulin+ cells within undifferentiated PMP spheres, which also
displayed much lower insulin gene expression than mature
b cells. However, these cells evinced comparable or elevated
levels of the transcription factors PDX-1, Nkx6.1, and Ngn-3,
indicating that they had a precursor character or were immature
proto-b cells derived from the PMP. These findings are also
consistent with a mechanism in which the PMP-derived cells
are reactivating portions of pancreatic developmental genetic
programs in the generation of new pancreatic cells.
The finding that mouse PMP cells express insulin in vivo is of
particular note, because it provides partial reconciliation with
the work of Dor et al. (2004), which argued that new b cells
were derived exclusively from pre-existing ones. Because the
precursors express insulin, simple insulin expression-dependent
lineage labeling of b cells cannot discriminate between self-repli-
cation of existing mature b cells and proliferation and differenti-
ation from insulin+ stem cells. Total reconciliation with
Dor et al. (2004) has not been achieved, because they do not
observe the production in vivo of non-b cells in their lineage-
tracing experiments. To the contrary, we demonstrate that
insulin+ cells give rise in vivo to multiple pancreatic and neural
cell types in the normal adult pancreas, thus corroborating this
in vitro demonstrated bilineage multipotentiality of PMP cells
and establishing that this potential was not a culture artifact. It
is possible that this discrepancy is due to the increased sensi-
tivity of the transgenic insulin-lineage marker used in the current
study, because Dor et al. (2004) used alkaline phosphatase,
whereas we used a GFP signal amplified by a secondary anti-
body fluorophore, which would be expected to yield enhanced
detection. Indeed, the absence of evidence for in vivo non-
b cell contribution in Dor et al. (2004) is not evidence of absence290 Cell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc.for this capacity. Similar to Dor et al. (2004), we do not observe an
increase in the percentage of insulin+ cells labeled with GFP over
the chase period in vivo, suggesting that there is proportional
contribution to new b cells from replication of labeled and unla-
beled existing b cells and PMP cells. Occasionally, we would
observe an entirely GFP+/insulin+ cell cluster (typically <10 cells),
though no large islets that were entirely GFP+, which would be
the case if the islet was wholly derived from a labeled PMP cell.
Several other studies have utilized various experimental and
modeling techniques to suggest that all b cells have equivalent,
and very slow, replication rates and that precursors do not play
a role in maintaining adult b cells (Teta et al., 2005, 2007;
Brennand et al., 2007). Reasons for the discrepancies between
these and the current study are unclear, but it is quite possible,
given the rarity of PMPs, that they were simply missed. For
example, in Brennand et al. (2007), the same RIP-Cre-ER mice
used in the current study were utilized in combination with the
mosaic analysis with double markers (MADM) system, a tech-
nique that allows low-frequency lineage labeling of insulin+ cells.
After a chase period, the clones from such labeled insulin+ cells
were analyzed, and they were found to all be of equivalent size,
without any large clones being evident. The authors use these
data to argue against the existence of any highly replicative
insulin+ precursors, but their technique labeled only
0.1%–.05% of insulin+ cells, and thus PMPs would easily have
been overlooked. Related to this, a pertinent point is that
whereas PMPs display high replicative capacity within our
in vitro sphere-formation assay, it is unlikely that they proliferate
in vivo at the same rate and to the same extent. One must be
cognizant that we are employing potent mitogens in the
sphere-formation assay to reveal proliferative ability, which
almost certainly manifests to a lesser degree in vivo, especially
in the uninjured adult pancreas. It therefore remains likely, and
consistent with our findings, that b cell replication remains
amajormechanism for normal adult b cell homeostasis, although
it is also likely that this mechanism cannot fully account for the
extensive expansion occurring during early postnatal life, preg-
nancy, and in certain regenerative states. Indeed, recent
modeling of the dynamics of rodent postnatal b cell mass expan-
sion and maintenance revealed a large (80%) dependence on
nonreplicative sources (Manesso et al., 2009), supporting the
existence of a precursor cell compartment.
In the current in vivo lineage-labeling studies, the notably
increased appearance of GFP+ non-b cells over the chase period
clearly establishes the in vivo relevance of PMPs to normal non-
b cell turnover. A recent study demonstrated that in a certain
injury model inducing b cell regeneration (partial duct ligation),
endogenous tissue-resident multipotent precursors were acti-
vated in a facultative and Ngn-3-dependant manner (Xu et al.,
2008). The authors show the expansion of Ngn-3+ cells in the
tissue during regeneration and demonstrate the production of
multiple islet cell types in vitro from Ngn-3+ cells. It is quite
possible that the originating precursor cells may be our PMP
cell population, as we (Figure S4) and others (Gu et al., 2002;
Dror et al., 2007) have demonstrated the presence of
insulin+/Ngn-3+ cells in the normal adult pancreas.
Other studies have suggested that under specific culture
conditions, b cells can undergo a process of epithelial-to-
mesenchymal transition (EMT), a process by which epithelial
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characteristics and acquire features associated with mesen-
chymal cell types (Gershengorn et al., 2004; Ouziel-Yahalom
et al., 2006; Russ et al., 2008). After EMT of b cells, the resultant
fibroblast-like cells can be extensively expanded, followed by
‘‘redifferentiation’’ into pancreatic endocrine cell types. Such
EMT of b cells may also provide reconciliation with the findings
of Dor et al. (2004), albeit through a different mechanistic inter-
pretation than our model of resident insulin+ stem cells.
However, most of these EMT studies do not utilize any lineage-
labeling techniques to verify that the proliferative fibroblast-like
cells are specifically derived from b cells. Indeed, several recent
studies with lineage-tracing techniques found that such islet-
derived fibroblast-like cells were not derived by EMT from either
PDX-1- or insulin-expressing cells but rather were MSC-like
cells, similar to those isolated from bone marrow (Chase et al.,
2007; Atouf et al., 2007). This is in contrast to the work of
Russ et al. (2008) in which lentivirus-based GFP insulin lineage
labeling was performed to support human b cell EMT. However,
with this technique, a substantial percentage (30%) of theGFP-
labeled cells were insulin negative (andmany of these were posi-
tive for other islet hormones) when examined 4–5 days after viral
infection, consistent with our interpretation of the presence of
insulin+ multipotent precursor cells. Support for the dissimilarity
between PMP-derived and true (bone marrow-derived) MSC
populations was obtained by RT-qPCR analysis for key genes
(Figure S5). Although the PMP spheres expressed substantially
higher levels of nestin and comparable levels of vimentin to
MSCs, the expression of pancreas-associated genes was
absent from the MSC samples, verifying the nonequivalence of
these populations.
A recent study (Stanger et al., 2007) suggested that the final
size of the pancreas is determined by the number of embryonic
progenitor cells, each with an autonomous restriction on the
amount of tissue it was capable of generating (i.e., nonstem
cells). The authors draw comparisons to the intrinsic ‘‘counting
mechanism’’ that had been initially suggested to limit the number
of times a central nervous system oligodendrocyte precursor cell
can divide (Temple and Raff, 1986). However, such intrinsic limi-
tations clearly do not exist with the PMP cell population
described in the current study, because each PMP can generate
many b and other differentiated cells when given the appropriate
conditions. As well, PMPs demonstrate some capacity for self-
renewal in vitro and can be isolated from both mouse and human
throughout the entire lifespan, suggesting maintenance of this
population in vivo. Thus, the limitation on PMP cell contribution
in vivo appears to be cell extrinsic. This is also the case for the
above-mentioned oligodendrocyte precursors, which were later
found to be free of ‘‘counting mechanism’’ limitations when
provided with specific growth factors in vitro, ones that are upre-
gulated in the brain in response to injury in some cases
(Wolswijk and Noble, 1992).
Though much of the present characterization of PMP cells
relied on the use of mice and their genetic tractability, any envis-
aged application of pancreatic precursors in therapeutic b cell
replacement strategies would obviously be facilitated by the
use of human-derived cells. To that end, we have demonstrated
the presence of a multipotent PMP cell population in the islets of
adult human pancreatic tissue. A single differentiated humanPMP colony was found to contain 11% b cells and 3.3 ng of
insulin, whereas a human islet contains 55% b cells (Brissova
et al., 2005) and contained 45.5 ng of insulin. Thus, the insulin
content of PMP-generated b cells was 36% of primary human
b cells. Further, the de novo generated human b cells were
shown to display functional regulated insulin release. Under
basal low-glucose conditions, differentiated PMP colonies
released 39 pg insulin/colony/hr, a value 18% of that typically
obtained in our lab from individual human islets under similar
conditions (unpublished observations). Taking into account the
differing numbers of b cells (11%, PMP colony; 55%, islet), the
basal insulin release from human PMP-derived b cells, on a per
b cell basis, was90% of that released from human islet b cells.
These promising functional data led us to undertake the trans-
plantation experiments, in which an amelioration of hypergly-
cemia and weight loss was observed in mouse and human
PMP sphere recipients. The magnitude of the demonstrated
glycemic improvement is actually an underestimation, because
the glucometer range maximum was 33.3 mM glucose and
many of the nontransplanted mice reached this measurement
ceiling at many time points. Postanalysis of the grafted kidneys
revealed the presence of transplant-derived insulin-expressing
cells. The perseverance and evident functionality of these cells
suggest that they developed access to the vasculature, enabling
both nutrient supply and gas exchange as well as providing
conduits for blood glucose sensing and insulin release. Given
the insulin+ nature of PMPs and some of the precursors within
PMP spheres, it is possible that some of these insulin-expressing
cells derived from the grafts do not represent mature b cells (and
maintain a precursor identity); however, the clear effect on meta-
bolic parameters (blood glucose, weight) and the demonstration
of substantial circulating human C-peptide indicate that many of
them must have matured to functionality. Such findings provide
the basis for further investigation of the therapeutic potential of
these multipotent putative adult pancreatic stem cells.
EXPERIMENTAL PROCEDURES
Animals, Human Tissue, Cell Isolation, and Culture
All studies were approved by the Office of Research Ethics at the University of
Toronto. Mice used in these studies included wild-type BalbC and CD1,
NOD-Scid (Charles River), the Z/EG reporter strain, Wnt1-Cre, PDX-1-Cre,
MIP-GFP, and RIP-Cre-ER mice. Pancreatic islet and ductal tissue was iso-
lated and processed as previously described (Seaberg et al., 2004). MSC
populations were derived from the femurs and tibias of CD1mice as previously
described (Itoh and Aubin, 2009). PMP spheres were successfully obtained
from adult mice ranging in age from 4 weeks to >18 months, though exper-
iments were typically initiated with 5- to 10-week-old mice. Human islet tissue
(postmortem) from 17 donors ranging in age from 19 to 71 years (9 male,
8 female) was isolated according to the Edmonton Protocol and generously
provided via J. Shapiro and the Human Islet Distribution Programat theUniver-
sity of Alberta. Human islets were handpicked to ensure purity. All human
samples yielded PMP spheres. The PMP sphere formation assay was per-
formed as previously described (Seaberg et al., 2004); see Supplemental Infor-
mation for details.
FACS
Pancreatic cells were isolated as described, and cells were sorted with an
EPICS Elite Cell Sorter (Beckman-Coulter) or a FACSAria System (BD Biosci-
ences). All cells from the various transgenic mice were sorted into positive and
negative cell fractions on the basis of GFP fluorescence. Glut-2 sorting was
performed after immunostaining live cells with a primary anti-Glut2 rabbitCell Stem Cell 8, 281–293, March 4, 2011 ª2011 Elsevier Inc. 291
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Insulin+ Stem Cells in the Pancreasantibody followed by staining with an Alexa-647 goat anti-rabbit secondary
antibody. Experiments involving sorting populations followed by their plating
in the PMP sphere formation assay were performed 3–4 times. Quantification
of spheres from the sorted fractions are reported both as the percent of total
spheres derived from the positive and negative fractions, as well as average
sphere formation frequency values for the two fractions, as indicated in
the text.
Immunocytochemistry
Fixation and immunocytochemical analysis of cells was performed as
described previously for neurospheres (Tropepe et al., 1999); see Supple-
mental Information for additional details.
Insulin Release and Content Studies
Insulin release and content experiments were generally performed as previ-
ously described (Seaberg et al., 2004); see Supplemental Information for
details and modifications.
Transplantation Studies
Transplants were performed with BalbC PMP spheres into BalbC recipients
and human PMP spheres into NOD-Scid recipients. Recipients were made
diabetic with a single intraperitoneal injection of streptozotocin (170 mg/kg
BalbC and 125mg/kg NOD-Scid) in a pH 4.5 citrate buffer 7 days prior to trans-
plant. Blood glucose was measured from tail vein samples with a OneTouch
Ultra 2 glucometer (LifeScan). Recipient and control group mice were selected
based on nonfasted hyperglycemic (>16 mM) measurements for two
consecutive days (day 2 being the transplant date). 500 mouse islets,
400–500 mouse PMP spheres, or 350–400 human PMP spheres were
transplanted underneath the kidney capsule of recipient mice according to
Szot et al. (2007). Nonfasted blood glucose was measured twice weekly for
50 days posttransplant, after which final weights and plasma samples were
collected, mice were fixative perfused, and kidneys were harvested. Human
C-peptide was measured in plasma samples with an ALPCO ELISA
80-CPTHU-E01.1 Kit according to manufacturer’s instructions.
Statistics
Data are expressed as means ± SEM unless specified otherwise. Statistical
comparisons between two groups was performed with a t test where appro-
priate or by one-way analysis of variance (ANOVA) with Dunnett’s posttest
for comparing groups to control or the Bonferroni posttest for comparisons
between groups where an acceptable level of significance was considered
at p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
doi:10.1016/j.stem.2011.01.015.
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